Latest / MD Longevity Lab: Playing the Long Game with Drs. Vikas and Nisha Patel / 26. GLP-1 Series, Part 1: The Biology, the Drugs, and Why the Benefits Go Deeper Than the Scale
Transcript
- 0:00Between our patients, our social circuit, I don't even know how
- 0:04to estimate how many metric ton have been lost from using GLP
- 0:10ones. Seriously, these drugs work.
- 0:12They're effective, they're incredible tools.
- 0:15That's not the debate. The debate is what you're
- 0:18losing, because the scale doesn't always tell you that
- 0:21muscle is an organ. It's the organ of longevity.
- 0:26It regulates your blood glucose. Muscle is what protects your
- 0:30joints from injury. Muscle is what's going to keep
- 0:33you out of a nursing home. If I asked you, hey, I can get
- 0:39that number on the scale down 10 more pounds, but I need to take
- 0:44out one of your kidneys, would you do it?
- 0:54Welcome to MD Longevity Lab, where we're playing the long
- 0:56game. This is a podcast where science
- 0:59meets real life, with expert insights, practical tips, and
- 1:02real world tools to not only live longer, but live better.
- 1:06Our aim is to radically change the way medicine is practiced
- 1:10and enable individuals to age gracefully, maintaining health,
- 1:14span and vitality well into their later years.
- 1:17We're your host, Doctor Nisha and Dr. Vikas Patel, physicians,
- 1:21partners in life, and parents, balancing work, Wellness and
- 1:25everything in between. Let's dive in.
- 1:32Welcome back to the MD Launch OV Live podcast.
- 1:34Thanks for joining us, Anish. How is your week going?
- 1:39It's been a long week, I got to say, but it was very productive
- 1:44and I did try my first ever Reformer Pilates class.
- 1:51This week. How'd that go?
- 1:52Well, considering I'm normally like a power lifter, not a
- 1:58Pilates girl, it was it was definitely new for me.
- 2:03My friend Kate teaches the class, and I was always
- 2:07intimidated and she's been telling me to come and I finally
- 2:11came. And truth be told, I always have
- 2:14this fear with those reformers. Like I would somehow find a way
- 2:19to hang myself. It's like a medieval, you know,
- 2:23torture device and one of those wires that I would ruin the
- 2:26class. And just like, that would be my
- 2:28end game, like final Destination.
- 2:31I envisioned myself dying on a reformer.
- 2:35You're ridiculous and it turns out you're alive.
- 2:39So how the class go? As it turns out, I loved it.
- 2:46It was. I thought it was way better than
- 2:49let's say floor Pilates because or hot Pilates for two reasons.
- 2:54I feel like it engaged all my muscle groups and I was shaking
- 2:59by the end of the class. But a double whammy was I was
- 3:03pretty much in zone 2 the entire class.
- 3:06So for me it was two birds with one stone in that I was
- 3:10obviously doing mobility for Pilates, a little bit of
- 3:13strength training and burning fat all at the same time.
- 3:16So I never went into zone 3 so I would 100% do it again.
- 3:21I'm glad that you're a Pilates grown now.
- 3:23There you have it guys. I've I've been converted.
- 3:29All right, let's get started on today's podcast Question for the
- 3:35crowd. Have you heard of Ozempic?
- 3:38Who who has not heard of Ozempic?
- 3:41It's basically a household name at this point.
- 3:44Your neighbors on it, your friends on it, your Co workers
- 3:47on it. There's literally Saturday Night
- 3:50Live skits on it, and let's just acknowledge the literal elephant
- 3:57in the room or the missing elephant in the room, because
- 4:00between our patients, our social circle circle, I don't even know
- 4:06how to estimate how many metric ton have been lost from using
- 4:11GLP ones. Seriously, these drugs work,
- 4:14they're effective, they're incredible tools.
- 4:17That's not the debate. The debate is what you're losing
- 4:21because the scale doesn't always tell you that.
- 4:23And that's a nuance of GLP ones. And I think that's the topic
- 4:28that we want to cover today. GOP ones are genuinely
- 4:33revolutionary. The science behind them is
- 4:36extraordinary. But the conversation around
- 4:39them, at least in pop culture, has been either very
- 4:43oversimplified or polarized. You know either of these drugs
- 4:47are like complete miracles that just melt fat away while you're
- 4:52sleeping, or they're cheating and you're going to turn into a
- 4:56frail, muscle wasted version of yourself.
- 4:59Yeah. And as physicians and as people
- 5:02who have built a practice around evidence based medicine, we want
- 5:06to have that real conversation with you that that conversation
- 5:10that includes the biology, the data, the contacts, and honestly
- 5:15the things that no one wants to say out loud.
- 5:17So today, and I want to be upfront about this, this is a
- 5:21longer episode. It's actually A2 parter because
- 5:25there's genuinely just too much important science here to do
- 5:30justice in just one episode. So we're going to go pretty deep
- 5:35into GLP, one receptor agonist, GIP agonist, dual agonist like
- 5:41tirzepatide, and then the brand new oral pill formulations that
- 5:47a lot of people don't even know are out there.
- 5:49And then we're also going to try and preview Retta or Retta True
- 5:53Tide, which is a triple agonist that's in late stage trials and
- 6:00may also kind of reset the ceiling on what's possible.
- 6:04I know there's a lot of people who are already unofficially
- 6:08taking Redda. Yeah, they're buying it from
- 6:10like graymarket.com or Reddit threads.
- 6:14The number of times if I had a nickel for every time a patient
- 6:18asked me. Have you heard of Retta?
- 6:20Like Retta, Like it's a name, but it's not.
- 6:23We'd be retired, but that's not the way life works.
- 6:29So Part 1 today is a setup. We're going to discuss the
- 6:33evolutionary biology, the pharmacology, the new pill
- 6:37formats, and the remarkable, the remarkable benefits beyond just
- 6:42weight loss that are not getting enough attention.
- 6:46Part 2, we're going to drop right alongside this in a few
- 6:50weeks. It's where we get into the hard
- 6:51stuff, muscle loss, clinical data and what you need to be
- 6:56successful on the GLP ones. What happens when you stop them,
- 7:00right? Because the compounding pharmacy
- 7:04situation is a Wild West. So definitely look into a little
- 7:10bit on how to frame this. So we should also, Nisha brought
- 7:15up talking a little bit about the evolutionary biology behind
- 7:18this. I think that's important because
- 7:22if you can't understand why these drugs actually work so
- 7:25dramatically or why our modern food environment has truly
- 7:30created this problem in the first place, that is very
- 7:34helpful in setting up the mismatch between the bodies that
- 7:38we've inherited and kind of the world or environment that we've
- 7:42built around us. Most definitely, by the end of
- 7:45this episode, you should hopefully walk away with an
- 7:47understanding not just what these drugs, these GLP ones, do,
- 7:51but how to think about them, how to use GLPS GIPS intelligently,
- 7:56if you use them at all, and why a pill alone or an injection
- 8:01alone, no matter how powerful, will never be the entire answer.
- 8:05It's not that simple. All right, so let's get into the
- 8:08niche. Why don't you start us off here?
- 8:10All right. Can we just talk about the scale
- 8:14of session for a second? Because it makes me crazy.
- 8:17I mean, there's lots of things that make me crazy.
- 8:22But that most of this last week. Most of this last week made me
- 8:25crazy, but this makes me insane. Not your former class.
- 8:29Though no, my reformer class was totally calming.
- 8:31I would do it again. We, our oldest, had tennis
- 8:36tryouts at 6:00 AM every day this week.
- 8:38We hosted a Japanese exchange student for the week.
- 8:42Which was great, yeah. It's a lot of work, great
- 8:44experience, but yeah, it was definitely cramming more into
- 8:48our lives than we can handle. But anyway, back to the scale of
- 8:54session. People will text me all the
- 8:56time, right? My friends, I hit a plateau on
- 8:58my GLP one and the my first question is always are you
- 9:03resistance training? Are you hitting your protein?
- 9:06And usually the answer is no, right?
- 9:09They're drinking alcohol, starving themselves, or eating
- 9:14whatever sounds tolerable. Loving the way that they look in
- 9:17clothes. But naked is probably a whole
- 9:21different story. Still obsessing over that number
- 9:24on the scale. So what do they do?
- 9:26They go up on their dose of GLP one and that scale moves again
- 9:31and they're thrilled. But what just happened?
- 9:35They didn't lose fat, they lost muscle, right?
- 9:38And I want people to hear what Nisha's saying here because this
- 9:43is kind of the single most important part of the the nuance
- 9:48in the entire GLP One conversation.
- 9:51Yep, muscle is an organ, right? We've said that in previous
- 9:56episodes. It's the organ of longevity.
- 9:59It regulates your blood glucose. Muscle is what protects your
- 10:04joints from injury. Muscle is what's going to keep
- 10:07you out of a nursing home, and it's the thing that stands
- 10:10between you and frailty at 75, and you are burning fat at rest
- 10:18when you have more muscle. So it's not just the number on
- 10:22the scale that you want to worry about, it's the difference
- 10:25between fat and your femur. I think the analogy is always
- 10:30kind of jarring, but it is accurate.
- 10:32Yeah, I want people to really hear this.
- 10:35So let me ask you something. Everyone think if I asked you,
- 10:41hey, I can get that number on the scale down 10 more pounds,
- 10:46but I need to take out one of your kidneys.
- 10:50Would you do it? What if I said I'll remove a
- 10:55chunk of your femur, your hip bone, right?
- 10:59Just to watch that number drop on a scale?
- 11:02You would say absolutely not. That's crazy, but that's what's
- 11:08happening with unregulated GLP one use.
- 11:12People are on these high dose GLP ones Willy nilly.
- 11:15No protein target, no resistance training, no DEXA scan 0 plan,
- 11:21and they are burning through their most protective organ for
- 11:25the sake of a number, right? And then they come off the drug
- 11:30and they gain the fat back, but the muscle, that muscle doesn't
- 11:35come back. And that muscle is never going
- 11:38to come back without that serious work.
- 11:40So my rant is over. Let's get into why any of this
- 11:44is happening in the first place. Thank you for the rant.
- 11:49All right, we're going to get there.
- 11:50So I want to start with the foundation that makes all this
- 11:55really makes sense, and that's really evolutionary context.
- 11:59Because if you don't really understand why these drugs are
- 12:03so powerful in the way they work, you're not going to
- 12:06understand some of the stakes of using them incorrectly.
- 12:11So let's go back, you know, 200,000 years.
- 12:17I love how you drawn history and we love a good prehistoric cold
- 12:22open. 200,000 years so early Homo sapiens life is physically
- 12:30pretty demanding. Calorie acquisition requires
- 12:34true effort. You're you have to hunt forage.
- 12:39You have to carry food long distances after you catch it or
- 12:43gather it. You have to actually find ways
- 12:46to process it. Calories are scarce and they're
- 12:50pretty unpredictable, often seasonal.
- 12:53You might eat really well for one week and then almost eat
- 12:57nothing the next week. And that's not really a that
- 13:03that we have to keep that into context because we have to
- 13:07understand what our body does that allows us to survive and
- 13:12reproduce. It has to do with how we are
- 13:15actually storing those calories when they are in abundance, and
- 13:17then what happens when they're scarce.
- 13:19For sure, it's a body that is exquisitely good at finding and
- 13:24eating calorie dense foods, storing energy efficiently, and
- 13:29being very reluctant to give that energy back.
- 13:32And that's not a flaw. That's precisely what kept the
- 13:36lineage alive for thousands of years.
- 13:38Exactly. Evolution gave us incredibly
- 13:42powerful biological drives. They gave It gave us reward
- 13:46circuits that light up intensely for fat storage and to crave
- 13:52sugar. It gave us hunger hormones that
- 13:55are persistent and persuasive in our daily life, and a metabolic
- 14:01governor that down regulates when you lose weight to try to
- 14:06get that weight back. Every single one of those
- 14:09mechanisms was truly a survival advantage when calories are
- 14:13scarce. And this is the fundamental
- 14:17evolutionary mismatch we talked about so much in our framework.
- 14:21The biology is ancient. The food environment that we
- 14:25live in is brand new. We basically have taken we we
- 14:31took the most hyper palatable calorie dense substances that
- 14:37humans could ever engineer. Refined carbohydrates, seed
- 14:41oils, ultra processed foods with perfectly calibrated ratios of
- 14:47salt, fat and sugar. And we made them super cheap,
- 14:51abundant and basically inescapable.
- 14:55And then we're surprised that people are gaining weight as if
- 14:59willpower is going to win against millions of years of
- 15:03selective pressure telling your brain when calorie dense food is
- 15:08available, go and eat it. Yeah, the data on this is
- 15:11sobering. In 1960, about 13% of Americans
- 15:16were obese. But in 2020, that number was 42%
- 15:21more than tripled. And the rates of severe obesity
- 15:25ABMI over 40 has quadrupled. And over that same period of
- 15:31time, we were telling people to eat less and move more.
- 15:35If that advice wasn't sufficient, we would have seen
- 15:38different numbers. So let's talk about the specific
- 15:42hormonal machinery involved, because this directly sets up
- 15:46why GLP ones really work so well.
- 15:50There are two major hunger related hormone systems you need
- 15:54to understand. The first is ghrelin, the hunger
- 15:58hormone itself. It's produced in your stomach,
- 16:01rises before meals, falls after eating, and acts on your brain
- 16:05to increase appetite and then drive you towards food.
- 16:09Yeah. And the second system involves
- 16:11satiety signals, and those are hormones that tell you to stop
- 16:15eating like when you're full, right.
- 16:18The most important ones for our conversation today are GLP one,
- 16:22which stands for Glucagon, like peptide 1, and GIP, which stands
- 16:28for glucose dependent insulinotropic polypeptide.
- 16:32So these are released by your gut.
- 16:35So they're naturally occurring substances in your gut that
- 16:38respond to food and they do several things simultaneously.
- 16:43They stimulate insulin secretion, they suppress
- 16:46Glucagon, they slow gastric emptying.
- 16:49And critically, they signal the brain, especially a region
- 16:52called the hypothalamus in your brain to reduce appetite and
- 16:56create satiety. So that's that feeling of being
- 16:59full. And here's the key problem in
- 17:03modern obesity, that satiety system is often dysregulated or
- 17:09overpowered. The reward signal from ultra
- 17:12processed foods can overwhelm the satiety signal.
- 17:17You eat a, you know a bag of chips and your GLP 1 and GIP,
- 17:22they go up. Your brain knows you consume
- 17:25calories, but the dopamine hit from the engineered palatability
- 17:31of those chips keeps driving the behavior despite the signals.
- 17:37The stop signal basically just gets drowned out.
- 17:40And on top of that, for many people with obesity, there's
- 17:44evidence that the GLP one response itself just becomes
- 17:48blunted, meaning the satiety signal is less robust to begin
- 17:53with, which further tilts the playing field.
- 17:57So you have a food environment that's really engineered for
- 18:02over to override your satiety, a reward system evolved to never
- 18:07say no to available calories, and then a satiety hormone
- 18:12that's already just underperforming.
- 18:15This is not really a fight that you can win with just willpower.
- 18:21There's another piece of this that doesn't really get talked
- 18:24about enough and there's neuroimaging data.
- 18:30Studies using brain Mris have shown that people with obesity,
- 18:36people with obesity showing images of high calorie food
- 18:40produces greater activation in those reward centers.
- 18:44The nucleus accumbens, which is the in the orbital frontal
- 18:50cortex in if you compare that to people with normal weight, the
- 18:57overweight people have over activation in those reward
- 19:01centers. The brain is literally just more
- 19:04reactive to those food cues. And here's the remarkable thing
- 19:09about GOP one medications. Those same neuroimaging studies
- 19:12done on patients taking stomach glutide show dramatically
- 19:16reduced activation of those reward centers in response to
- 19:20the same food images. The drug is not just like
- 19:23reducing hunger, it's also quite that neuro neurological clamor
- 19:29going on in the brain. Yeah, what you're saying is this
- 19:32is what patients mean when they're talking about that food
- 19:35noise, that that constant quest for food or junk and that goes
- 19:41away. So it's not a metaphor.
- 19:43It's measurable neurobiology. And I think that's one of the
- 19:47most profound reframes in all of metabolic medicine right now.
- 19:52The shame and moralizing around weight is it's really not
- 19:57helpful. It's scientifically unaccurate.
- 20:00So our biology is not a character flaw, and I think
- 20:05that's what all of us failed to recognize.
- 20:08And before we move on, I want to add one more evolutionary thread
- 20:12here because it connects directly to why the compounding,
- 20:18you know, access crisis that we're going to discuss in Part 2
- 20:21matters so much. We evolved to respond to famine,
- 20:28not really to respond to abundance, because there was no
- 20:32abundance. The mechanisms for shutting off
- 20:35eating in an environment of unlimited engineered hyper
- 20:39palatable food. We just we don't have those.
- 20:44We never needed them through our entire evolution, and the drugs
- 20:49we're about to discuss are, in a sense, the first time that
- 20:53medicine has been able to pharmacologically insert that
- 20:58missing piece for us. All right, so let's dive into
- 21:03the drugs themselves and get into the pharmacology.
- 21:07And I want to do this in a way that's clinically honest without
- 21:12turning it into a true pharmacology lecture.
- 21:16Nisha, why don't you walk us through the generations of these
- 21:20drugs? Sure.
- 21:21So the drugs that really made headline several years ago were
- 21:25Lyra glutide, which is Victoza Saxenda and then semaglutide
- 21:30which most people know as Ozempic for type 2 diabetes or
- 21:35Wegovi for obesity. So semaglutide is a synthetic
- 21:40version of our natural GLP one hormone.
- 21:42So we all produce like we mentioned GLP, one hormone
- 21:45naturally in our gut and it is engineered to stay in the body
- 21:50for far longer in these pharmacological forms.
- 21:54So natural GLP one breaks down in minutes and semaglutide has a
- 21:58half life of about a week, which is why normally this is a once a
- 22:03week injection. So the weight loss results in
- 22:06these step trials were remarkable, about 15% of average
- 22:11body weight loss over 68 weeks. So just over a year prior anti
- 22:18obesity meds it was about 5 to 8%.
- 22:21So really, these meds were the first on the market to kind of
- 22:26'cause this cascade of real profound weight loss.
- 22:30Yeah, then we got tirzepatide. So Montjerno is the branded
- 22:36version for diabetes, same drug Zep bound for obesity and this
- 22:42is different because it was a dual agonist targeting both the
- 22:46GLP one as well as the GIP receptor simultaneously.
- 22:52So there's this trial, the SURMOUNT trials showed even more
- 22:56impressive results than the Ozempic trials.
- 23:00So the highest dose achieved about 22% average total body
- 23:06weight reduction with some patients losing 30% or more that
- 23:11approaching. That's approaching what we used
- 23:14to see really only with bariatric surgery.
- 23:17Yeah, those gastric sleeves, right?
- 23:19Sleeve or gastric bypass surgery and you're getting all this just
- 23:23with a weekly subcutaneous injection.
- 23:25Mechanistically, the addition of the GIP activity seems to work
- 23:31synergistically or in conjunction with the GLP one and
- 23:36not just in terms of weight loss but also in terms of
- 23:40tolerability. Many patients report they have
- 23:43fewer nausea side effects with tirzepatide than they did with
- 23:48some of glutide, which is really clinically meaningful because
- 23:52tolerability is often what determines whether someone can
- 23:56stay on a medicine medicine long term or not.
- 23:59Yeah. And then there's the next
- 24:00frontier that we talked about, Retta.
- 24:05Retta, which is a triple agonist, it's GLP, 1 GIP and a
- 24:11Glucagon receptor agonist all in one molecule.
- 24:15Phase two trials showed average weight loss of about 24% at the
- 24:20highest dose over 48 weeks, with some participants approaching
- 24:2540% total body weight reduction. Phase three trials are ongoing
- 24:31and the data coming out in the next year or two could really
- 24:35change the treatment landscape as we know it.
- 24:40The Glucagon component is what makes red a trutide so
- 24:45fascinating from a energy expenditure standpoint.
- 24:49Glucagon doesn't just suppress appetite, it actually increases
- 24:53thermogenesis and fat oxidation. So you're reducing intake and
- 25:00then on top of that you're actually increasing caloric burn
- 25:04simultaneously. It's a dual mechanism
- 25:07intervention in just this one single molecule.
- 25:10Mechanistically, all these drugs work both centrally in your
- 25:14brain as well as peripherally acting on the hypothalamus in
- 25:19the brain and the hind brain to reduce appetite and quiet that
- 25:24food noise. While peripherally they're
- 25:26slowing gastric emptying in our stomach, they're stimulating
- 25:30insulin secretion in a glucose dependent way, and they're
- 25:35suppressing Glucagon from the pancreas.
- 25:39All right, so let's touch on side effects of all of these,
- 25:42right? Semaglutide, tirzepatide, Greta,
- 25:46the side effects. So we want to be honest here.
- 25:48The most common are these GI side effects, the
- 25:51gastrointestinal side effects, nausea, vomiting, Constipation.
- 25:56Sometimes patients get diarrhea. These are the most pronounced
- 25:59during the first few weeks of when you first start the
- 26:03medication or when we're increasing the dose and for most
- 26:06people that improve significantly with time, which
- 26:10is why slow titration is that standard protocol that we like
- 26:13to use. We like to keep patients on at
- 26:15least a month of the same dose before titrating up.
- 26:19There's also a subset of patients who experience more
- 26:22prolonged gastroparesis like symptoms, which is that slowing
- 26:26of the gut so they feel real constipated, bloated.
- 26:31There are ongoing discussions about that rare association with
- 26:34pancreatitis and gallbladder disease.
- 26:37This is why we counsel our patients not too heavily drink
- 26:40on these medications and these absolute risks remain low, but
- 26:45they definitely deserve this individual risk factor
- 26:48discussion. There's a FDA boxed warning
- 26:52about some thyroid C cell tumors and carcinomas based on some
- 26:57animal studies that have not yet been replicated in humans, but
- 27:02it remains A contraindication with a personal or a family
- 27:05history of medullary thyroid carcinomas or men too.
- 27:11These aren't trivial medications and they're not without risk.
- 27:15That's not a reason to necessarily avoid them when
- 27:20they're indicated. It's a reason to work with a
- 27:22physician who actually understands that, monitors them
- 27:25appropriately, and has a plan beyond just writing the
- 27:28prescription. I think especially initially,
- 27:32like during the pandemic in the ERI saw quite a few patients
- 27:36coming in with vomiting, with pancreatitis and those
- 27:41gastroparesis symptoms because the escalation of dose was
- 27:45happening too fast. The people who were prescribing
- 27:47them, I'm not knocking on nurse practitioners, but there was a
- 27:52lot of there's a lot of NP clinics that were that were
- 27:56writing these prescriptions not and writing them way too quickly
- 28:00starting people not on as an initial dose and that led to a
- 28:04lot of this. We don't see it nearly as much
- 28:06now all. Right.
- 28:08Let's move on to the pill form, these oral GLP formats, which
- 28:12are the new frontier of these medications.
- 28:14And this is one of the things that I'm genuinely most excited
- 28:17about because it expands access and these oral formats, because
- 28:22when most people are thinking about GLP ones, they think
- 28:25injections, they're weekly injections.
- 28:27And for a significant portion of patients, you don't needle
- 28:31aversion is a real barrier, right?
- 28:34It's much easier to take a pill than it is to inject yourself.
- 28:38100% The first oral GLP one to market was Rybelsus.
- 28:44It's oral summon glutide for type 2 diabetes.
- 28:48Actually available since 2019, but it has a very specific
- 28:52protocol that a lot of patients get wrong.
- 28:56I think that's the hard part. You have to take that oral
- 28:59medication on an empty stomach with no more than 4 ounces of
- 29:04plain water. Not coffee, not juice, tea,
- 29:08nothing else. And you have to wait at least 30
- 29:12minutes before eating, drinking or taking other medications.
- 29:15And the reason is that that GLP one, it is a peptide and
- 29:20peptides are normally destroyed in the stomach by our stomach
- 29:24acids and enzymes before they can even be absorbed by our
- 29:27body. So that oral semaglutide uses an
- 29:31absorption enhancer called snack and that briefly buffers that
- 29:36stomach pH and allows that semaglutide to absorb directly
- 29:40through the gastric mucosa. But I know how many of us, I
- 29:44mean, the first thing I do when I wake up in the morning, like
- 29:47before I even talk to him, like don't even look at me, I need a
- 29:49cup of coffee. So it is really hard to follow
- 29:53that protocol. Yeah.
- 29:56So you know that 30 minute fast, it's not arbitrary.
- 30:00It's pharmacologically essential.
- 30:04If you eat right away, absorption drops dramatically.
- 30:08This is the number one adherence failure we see with Rebelsis.
- 30:12People treat it like any other pill and it just isn't.
- 30:15Yeah, you can't take it with your blood pressure pills or
- 30:18cholesterol pills or your supplements, your vitamin D And
- 30:24I think that's a fallacy is a lot of people think because, oh,
- 30:28it's not as effective. No, you just have to take it
- 30:31correctly, which how many of us do.
- 30:33That's really hard. So weight loss from standard
- 30:37dose of these oral meds was definitely more modest than
- 30:41injectable form. And that's partly because of the
- 30:44bioavailability, which is inherently lower with the oral
- 30:48delivery. And we talked about the reasons
- 30:51why. And now some of these drug
- 30:54companies have developed higher dose formulations and they're
- 30:58testing it at higher doses specifically for obesity in
- 31:01people without diabetes. And the results were pretty
- 31:04striking. Average weight loss was about
- 31:0715% / 68 weeks, essentially matching what we saw in those
- 31:12injectable step trials. And that's the same efficacy
- 31:17from a pill as we get from a weekly injection, which is a
- 31:21huge pharmacological engineering achievement, right?
- 31:24If we can package something into a pill, it's much easier to
- 31:27deliver to patients. So the FDA approves oral
- 31:30semaglutide at 25 and 50 milligrams under the brand name
- 31:35of Waco V. So that's a real option for
- 31:37patients and really nice for those patients that don't like
- 31:41doing injections on themselves. What about the side effect
- 31:45profile of the pills? Yeah.
- 31:47Generally, these oral ones are pretty comparable.
- 31:50Some patients report GI side effects slightly more,
- 31:54especially when they're front loading and 1st starting the
- 31:56medication with the oral medication, the oral version
- 32:01versus the injectable one, especially at those higher
- 32:03doses. But that same slow titration
- 32:06protocol applies, right? We're not starting high dose
- 32:09right away and now there's oral turnipatide.
- 32:14The phase three trials are underway, which is really
- 32:16exciting. The phase two data was super
- 32:19promising and given how tirzepatide's injectable form
- 32:23that outperformed some of glutide and now there's an
- 32:27effective oral version coming out of tirzepatide.
- 32:31This would be a huge development and really kind of propel our
- 32:35patients forward. You know, we're excited to kind
- 32:39of see what's coming through the pipeline.
- 32:41So the broader point here is important.
- 32:45The barrier to these medications is changing pretty rapidly.
- 32:49A year ago, if you weren't comfortable with injections,
- 32:52your options were limited. Now there's general genuine oral
- 32:57options and they match pretty much the injectable efficacy.
- 33:04And there's also an active pipeline for these, you know,
- 33:10once daily formats, extended release tablets, even sublingual
- 33:15delivery. The technology around getting
- 33:18peptide drugs to survive oral administration, which was
- 33:23historically almost impossible, is advancing really fast and
- 33:28much faster than people expected.
- 33:30On just the front of patient selection, though the clinical
- 33:35decision it isn't purely about just like needle phobia, the
- 33:40oral stomach glutide requires a consistent fasting window, which
- 33:44is really a lifestyle consideration.
- 33:47Patients with unpredictable early schedules or who take
- 33:51multiple morning medications with food, they really may find
- 33:55that there's difficulty with adherence for patients, the once
- 34:02weekly injection, it actually has a simplicity advantage.
- 34:07You take it once any time of the day with or without food, and
- 34:11you're basically dumb. The key is really just matching
- 34:13that that effective regimen to the patient rather than matching
- 34:19the patient to the regimen. You had mentioned the
- 34:22bioavailability of peptides. There are so many patients
- 34:27spending boatloads of money on these oral peptides.
- 34:30I know I'm digressing GLP 1 is a peptide, but there's so many
- 34:34other peptides available. These Instagram ads of buy this
- 34:37peptide in this pill form. So really these are just really
- 34:42expensive formulations that you're peeing or pooping out
- 34:45because the bio available your stomach acid literally destroys
- 34:49these peptides right away. So like you said, these FDA
- 34:53approved studies are awesome because is it proves that they
- 34:57found the technology to make these oral peptides
- 35:00bioavailable, but that's not the supplement industry.
- 35:03I just wrote on our sub stack about about BP157BBC157.
- 35:13The total number of patients in a clinical trial that have
- 35:20received BPC 157 is 14. 14 people have used this compound
- 35:29in a clinical trial setting. There was another 42 that had
- 35:34gotten it. That trial was registered and
- 35:41closed in under a year and never reported any results.
- 35:45So then when, you know, some compounding pharmacy says that,
- 35:50oh, we have an oral formulation of this peptide available,
- 35:54where's the data that says that, oh, this is actually just as
- 35:58bioavailable as the injectable version, which we know is
- 36:02bioavailable? That's the Wild West.
- 36:04It's the complete Wild West. Yeah, it's like the cognitive
- 36:07dissonance. People are so willing to try a
- 36:11product that's never been tested, but when it comes to FDA
- 36:16approved medications like statins are like, I'm skeptical.
- 36:20I don't know, it just baffles me.
- 36:22That's crazy. Yeah.
- 36:25All right. So let's kind of talk about some
- 36:27of the clinical benefits beyond just the scale, right?
- 36:31And there are like true real benefits of these medications
- 36:37and it's worth spending some real time on.
- 36:39The systemic clinical benefits go far beyond what we see on the
- 36:43scale. These are not just weight loss
- 36:45drugs. Yeah.
- 36:47And this is where that longevity framework really crystallizes.
- 36:51You've talked about your six Horseman model, right?
- 36:55Metabolic dysfunction, which sits upstream of almost every
- 36:59major killer, cardiovascular disease, cancer, Alzheimer's and
- 37:04other forms of dementia, frailty and mood disorder.
- 37:08These are drugs that are hitting multiple nodes of that pathology
- 37:13simultaneously, and that's pretty extraordinary.
- 37:16Let's start with cardiovascular disease because this is pretty
- 37:19landmark and practice changing data.
- 37:23The SELECT trial with semaglutide was a massive study,
- 37:26right? 17,000 participants with who are
- 37:30overweight or obese and already have established cardiovascular
- 37:35disease. But critically, these few
- 37:37patients did not have diabetes. In this trial, it showed us that
- 37:41there was a 20% reduction in major adverse cardiac events.
- 37:46That means heart attacks, strokes, cardiovascular death
- 37:4920% and these are in people who are not even diabetic.
- 37:54Yeah, and the mechanism debate is pretty fascinating.
- 37:57The cardiovascular benefits of GLP ones appeared to exceed what
- 38:01you'd expect from normal weight loss alone, even accounting for
- 38:05that 15% body weight reduction. And these drugs seem to have a
- 38:10direct effect on inflammation and reducing it.
- 38:15So they reduce visceral adiposity which is not just
- 38:19cosmetically undesirable. You've heard us rants about
- 38:23visceral fat, Visceral fat which is that biologically active
- 38:27tissue which is pumping out pro inflammatory cytokines and free
- 38:32fatty acids directly into our circulation.
- 38:35These GLP ones have a profound impact on visceral fat, which
- 38:40has downstream effects on insulin sensitivity, blood
- 38:44pressure, your cholesterol, and your vascular inflammation
- 38:48simultaneously. So then there's the kidney data.
- 38:53The FLOW trial with some of Glutide in patients with type 2
- 38:57diabetes and chronic kidney disease showed a 24% reduction
- 39:02in the composite outcome of kidney, kidney disease
- 39:06progression and stage kidney disease and kidney or
- 39:10cardiovascular death. This is a population right
- 39:15diabetic patients with established chronic kidney
- 39:17disease where we have historically had very limited
- 39:21pharmacological options and truly very poor prognosis.
- 39:26The nephrology world really took serious notice of this.
- 39:29The liver data is also pretty compelling.
- 39:32So there's something called Nash, which is non alcoholic,
- 39:36stay out of hepatitis, basically fatty liver, which effects
- 39:41somewhere between 10 and 30% of Americans to varying degrees.
- 39:46And that's becoming the leading driver of liver transplant
- 39:49waiting list. Both semaglutide and tirzepatide
- 39:53trials have showed not just reductions in liver fat on
- 39:57imaging, but on histological studies, which is that if they
- 40:01do a liver biopsy and that's actual evidence of cellular
- 40:06healing. So that's not something we
- 40:08should just say about. Very many medications that
- 40:11literally at the cellular level, it's improving.
- 40:15All right. Now there is the neurological
- 40:18data. This is where I find things
- 40:20especially compelling from a really long game perspective.
- 40:24GLP one receptors are expressed throughout the brain, not just
- 40:28in the appetite centers. There is accumulating
- 40:31observational data and now emerging perspective trial data
- 40:38suggesting that GLP 1 Agnes use use is associated with
- 40:43meaningfully lower rates of Alzheimer's diagnosis and
- 40:47cognitive decline. One large analysis comparing
- 40:51some of glue dyed users to match controls on other diabetes
- 40:55medications found significantly lower rates of Alzheimer's with
- 41:02hazard ratios that were truly clinically meaningful.
- 41:06The EVOKE trials are now testing semaglutides specifically for
- 41:11Alzheimer's disease, and the scientific community is watching
- 41:15pretty closely. Yeah.
- 41:16The proposed mechanism include reduced neuro inflammation,
- 41:20improved insulin sensitivity signaling to the brain.
- 41:25Because we've coined right Alzheimer's, we call this type 3
- 41:30diabetes and a lot of researchers use that term right
- 41:34and it improves cerebrovascular health from the cardiovascular
- 41:39effects and possibly direct neuroprotective effects at that
- 41:43GLP, one receptor itself. We should also touch upon sleep
- 41:47apnea. So the SURMOUNT OSA trial with
- 41:51tirzepatide showed approximately a 50% reduction in apnea
- 41:57hypopnea index. If you understand the downstream
- 42:01effects of untreated sleep apnea, which are which is
- 42:05cardiovascular stress, cortisol dysregulation, glucose
- 42:09metabolism disruption, cognitive impairment, a 50% reduction in
- 42:16AHI is not a minor footnote. It's transformative truly for
- 42:24quality of life and for long term health.
- 42:27Yeah, there's also genuinely exciting emerging data on the in
- 42:32the addiction medicine space, which is really exciting.
- 42:36GLP 1 receptors in the mesolimbic dopamine pathway,
- 42:41that reward circuit that we get appear to modulate not just food
- 42:46reward, but reward seeking behavior broadly.
- 42:48So we have patients all the time that say, like, yeah, I'm not
- 42:51really craving that alcohol that I normally like to drink at the
- 42:55end of the night, or even their phone or whatever addictive
- 42:59behaviors that they're used to completing.
- 43:01So there are now clinical trials and observational analysis that
- 43:06show reduced alcohol consumption, reduced cravings
- 43:10and signals, and even an opioid use disorder as well.
- 43:15So this is opening up an entirely new chapter in
- 43:19addiction medicine, which is exciting.
- 43:22It's pretty fascinating because I think it really touches on the
- 43:25fact that we know that addiction is a central nervous system
- 43:29phenomena and the fact that these medications work in the
- 43:32central nervous system in these reward centers.
- 43:35It's going to be pretty fascinating to see what these
- 43:37results end up coming out as the clinical trials flows.
- 43:41I'll add one more that doesn't get talked about enough and
- 43:45really that's the early data on cancer risk reduction,
- 43:50particularly for obesity associated cancers.
- 43:53So those are commonly like the big major ones, though there's
- 43:58more colorectal, endometrial and pancreatic, the mechanistic
- 44:04pathways make some true biological sense.
- 44:07So you reduce insulin, you reduce IGF, one, reduce
- 44:13subsequently chronic inflammation.
- 44:16The observational data is beginning to bear this out.
- 44:19This is still emerging and we need a true prospective trial
- 44:24showing data, but there's definitely some signal there
- 44:27that these medications are reducing cancer rates.
- 44:31All right. So the big picture, take away
- 44:34GLP ones may be the most consequential pharmacological
- 44:40intervention in I would say medicine overall since statins
- 44:45perhaps so more consequential than statins.
- 44:50Would you agree? It's possible.
- 44:53I think we don't have enough time data yet, right?
- 44:58Statins. The number of deaths that
- 45:01statins have prevented is huge, but they've also been around for
- 45:06over 40 years now. I think we're gonna eclipse that
- 45:09in a much shorter period of time with the GLP GIP agonists.
- 45:14Yeah, but like statins, GLP ones need to be used thoughtfully,
- 45:20right in the right patients with appropriate monitoring, DEXA
- 45:25scan and as part of a broader health strategy, right, not as a
- 45:30vending mean a vending machine prescription that it's kind of
- 45:33become. I think this is probably a
- 45:36perfect segue because Part 2 of this series is where we really
- 45:42dig into exactly that. It's the hard clinical realities
- 45:46of muscle loss, of weight regain, that compound
- 45:51compounding pharmacy crisis, and what a genuinely intelligent
- 45:56protocol really would look like. But first, let's kind of bring
- 46:01home Part 1 here all. Right, Part 1 recap.
- 46:05What do we cover because. We started with that
- 46:08evolutionary foundation why our satiety biology was never
- 46:13designed for this current food environment that we've created.
- 46:18We talked about ghrelin, GLP, one GIP, the hyper palatable
- 46:23food problem, some of the neuroimaging data on reward
- 46:28center over activation, the biological reality that obesity
- 46:34it's just not a character flaw. Right.
- 46:37And we walked through the drug generations, semaglutide,
- 46:41tirzepatide, Retta, the injectable landscape from the
- 46:45first generation GLP one to the purple agonist, which may even
- 46:49break any record we've ever seen.
- 46:52We've covered the mechanism of action of these GLPGIP drugs,
- 46:56the trial numbers, the side effect profile and the patient
- 47:00selection nuance as well. We also covered the oral
- 47:03formats, Rybelsus, the new high dose oral semaglutide at 50
- 47:09milligrams matching truly like the injectable efficacy, the new
- 47:14oral tricepsatide trials and this category is just evolving
- 47:20pretty fast. Yep, And we spent time on some
- 47:23of the benefits beyond weight loss, cardiovascular benefits,
- 47:27liver healing, kidney protection, Alzheimer's
- 47:31prevention, addiction medicine, the addiction medicine frontier.
- 47:38These GLP one drugs are pretty remarkable.
- 47:41Part 2 is where we make all this clinically actionable.
- 47:46So we're going to cover the muscle loss data, why it matters
- 47:51for longevity, and what specifically to do about it.
- 47:55We're going to cover the weight regain issues, what the Step 4
- 48:01trials tell us, the homeostatic biology, and what lifestyle
- 48:06actually has to look like if you want to sustain long term
- 48:11results. We're also going to talk about
- 48:13the compounding pharmacy situation, what's safe, what's
- 48:17not and how to tell the difference.
- 48:20And then we'll kind of give the full, you know, 5-6 pillar
- 48:26protocol that we use at MD Longevity for patients who are
- 48:31on these medications. Yeah, Part 2 is a must for
- 48:36anyone that is on a GL P1. Don't just listen to Part 1 and
- 48:41skip Part 2. Part 2 is something I literally
- 48:45want to scream from the rooftops at everyone on one of these
- 48:49medications, which is so many people.
- 48:52And I can stand in the lineup and be like, you're going to
- 48:56fail, you're going to fail, you're going to fail.
- 48:57And I wish you had the Cliff notes for how to be successful
- 49:00on these meds because they've just been given these meds
- 49:03blindly and they're spinning their tires.
- 49:05So we do not want you guys spinning your tires.
- 49:08These medications are incredible tools if used correctly.
- 49:12I think one of the things that it's useful to think about,
- 49:16right? Like I totally get that some of
- 49:20glutide works, tirzepatide works better, and most likely Reddit
- 49:26trutide works even better. But for a lot of people who are
- 49:30not say morbidly obese, they don't need like the triple
- 49:38agonist right? Just because it works the best
- 49:42does not mean it's giving you the best outcome for your health
- 49:46Because how rapid the weight comes off.
- 49:48It's a problem if it's happening in a way that you're so calorie
- 49:53reduced that you're losing muscle at the same time that
- 49:57you're losing fat. So I think Part 2 will be a
- 50:00really good discussion about about how these medicines should
- 50:04be utilized. And I think we've made a big
- 50:07dent with patients, right? Like when we show them on their
- 50:10DEXA scan, especially the patients that are not morbidly
- 50:13obese that are on GLP ones. You lost 4 lbs of muscle and 2
- 50:18lbs of fat. Is this medication worth it?
- 50:21And for a lot of them that's a wake up call of do I need to be
- 50:25on this medication if I'm losing twice the amount of muscle as
- 50:29fat or for women who are my age? Doesn't make sense.
- 50:34Even if it's at a one to one ratio for most women, No way.
- 50:38We know how to gain the system so that we're not losing and you
- 50:43can. We're not losing muscle nearly
- 50:46as quickly as we're losing fat. And I think there's true utility
- 50:50in these drugs if you know how to use them properly.
- 50:54Yep, and we hope this episode's been useful.
- 50:58Please leave us a review, share it with someone who's been
- 51:01asking for Ozempic and getting a 10 second answer.
- 51:05So that's pretty much why we made this episode.
- 51:08We had a lot of requests to cover GLP ones.
- 51:11Yes. Also, please check out our new
- 51:14sub stack. I'm trying to put out articles
- 51:19that will take some of these topics a little bit more in
- 51:23depth. Other than that, we're going to
- 51:26hopefully catch up on some sleep this week.
- 51:28Yep, all right. Stay tuned for Part 2 where we
- 51:32cover GLPS and how to be successful on them.
- 51:40Thank you for playing the long game with MD Longevity Lab.
- 51:43You can visit us at www.mdlongevitylab.com to learn
- 51:48more about how we can support you on your dream.
- 51:51Stay connected with us on social media at MD Longevitylab for
- 51:55tips, updates, and behind the scenes insights.
- 51:58If you enjoyed today's episode, we'd love it if you subscribe,
- 52:01left us a rating, or shared it with someone you know who's also
- 52:04playing the long game. Thanks for listening, We'll see
- 52:07you next time.